Table 1.
Pulmonary leukocyte trafficking after rA2-line19F and A2 RSV infectionsa
| Day postinfection | Phenotype | Mean total no. of A2 cells ± SE (103) | Mean total no. of rA2-line19F cells ± SE (103) | % increase, A2 to rA2-line19F |
|---|---|---|---|---|
| 1 | CD3 | 3.96 ± 0.57 | 4.96 ± 0.39** | 18.90 ± 7.13 |
| CD4 | 0.22 ± 0.05 | 0.35 ± 0.09 | 33.77 ± 16.89 | |
| CD8 | 0.24 ± 0.02 | 0.49 ± 0.08*** | 49.53 ± 5.65 | |
| B cell | 2.42 ± 0.50 | 3.61 ± 1.31 | 27.67 ± 8.60 | |
| Macrophage | 4.95 ± 0.64 | 8.63 ± 0.94*** | 42.01 ± 9.54 | |
| PMN | 3.15 ± 0.72 | 4.76 ± 0.94** | 40.62 ± 9.64 | |
| NK | 1.86 ± 0.75 | 3.71 ± 1.14** | 49.86 ± 9.30 | |
| 3 | CD3 | 1.36 ± 0.61 | 5.33 ± 0.45*** | 73.55 ± 13.58 |
| CD4 | 0.20 ± 0.14 | 1.36 ± 0.35*** | 83.81 ± 13.45 | |
| CD8 | 0.16 ± 0.06 | 0.94 ± 0.09*** | 83.05 ± 6.07 | |
| B cell | 1.94 ± 0.76 | 5.50 ± 0.57*** | 63.11 ± 17.94 | |
| Macrophage | 6.57 ± 1.75 | 10.23 ± 1.31** | 36.09 ± 14.15 | |
| PMN | 0.35 ± 0.31 | 0.66 ± 0.12 | 41.07 ± 10.01 | |
| NK | 2.04 ± 0.70 | 4.71 ± 0.22** | 56.77 ± 19.98 | |
| 5 | CD3 | 4.69 ± 1.72 | 7.45 ± 2.56 | 37.05 ± 2.06 |
| CD4 | 0.96 ± 0.39 | 1.67 ± 0.50** | 56.62 ± 11.20 | |
| CD8 | 1.22 ± 0.46 | 1.66 ± 0.72 | 47.45 ± 14.18 | |
| B cell | 3.20 ± 0.94 | 13.64 ± 5.63** | 74.98 ± 7.18 | |
| Macrophage | 7.70 ± 0.71 | 25.13 ± 8.08** | 66.99 ± 8.42 | |
| PMN | 0.56 ± 0.21 | 0.72 ± 0.26 | 23.34 ± 4.28 | |
| NK | 3.94 ± 0.69 | 7.65 ± 1.70** | 54.26 ± 11.37 | |
| 8 | CD3 | 5.94 ± 1.10 | 18.20 ± 2.13*** | 67.27 ± 5.05 |
| CD4 | 1.29 ± 0.10 | 3.86 ± 0.45*** | 66.27 ± 4.56 | |
| CD8 | 2.20 ± 0.74 | 10.15 ± 1.25*** | 78.30 ± 6.59 | |
| B cell | 2.44 ± 0.55 | 3.11 ± 0.20 | 21.82 ± 5.06 | |
| Macrophage | 7.47 ± 0.49 | 10.59 ± 0.62*** | 29.14 ± 8.10 | |
| PMN | 0.90 ± 0.11 | 1.96 ± 0.22*** | 53.19 ± 10.21 | |
| NK | 4.40 ± 0.57 | 6.73 ± 0.43*** | 34.35 ± 10.22 |
BALB/c mice were infected with 1 × 106 TCID50 PFU of A2 or rA2-line19F RSV. Data are mean total numbers of BAL cells by subtype at day 5 p.i. per lung. Subtypes: lymphocyte gate, anti-CD3+ (17A2) and anti-CD4+ (GK1.5) CD4 T cells; lymphocyte gate, CD3+ and anti-CD8+ (53-6.7)− CD8 T cells; CD3− and anti-CD45R/B220+ (RA3-6B2)− B cells; CD3− and anti-CD11b+ (M1/70)− macrophages, dendritic cells, and monocytes; CD3− and anti-mouse Ly06G/Gr-1 (RB6-8C5)− polymorphonuclear cells (PMNs); CD3− and anti-mouse CD49b/integrin alpha 2 (DX5)− NK cells. **, P ≤ 0.05, as determined by ANOVA; ***, P ≤ 0.001, a significant increase in total BAL cell types in the rA2-line19F-infected group compared to the A2-infected group. Results are representative of two independent experiments for rA2-line19F challenge and mock challenge and one experiment for A2 challenge. The data are from no fewer than five mice per experiment.